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Abstract
Cancer cells frequently boost nucleotide metabolism (NM) to support their increased proliferation, but the consequences of
elevated NM on tumor de-differentiation are mostly unexplored. Here, we identified a role for thymidylate synthase (TS), a
NM enzyme and established drug target, in cancer cell de-differentiation and investigated its clinical significance in breast
cancer (BC). In vitro, TS knockdown increased the population of CD24+ differentiated cells, and attenuated migration and
sphere-formation. RNA-seq profiling indicated repression of epithelial-to-mesenchymal transition (EMT) signature genes
upon TS knockdown, and TS-deficient cells showed an increased ability to invade and metastasize in vivo, consistent with
the occurrence of a partial EMT phenotype. Mechanistically, TS enzymatic activity was found essential for maintenance of
the EMT/stem-like state by fueling a dihydropyrimidine dehydrogenase—dependent pyrimidine catabolism. In patient
tissues, TS levels were found significantly higher in poorly differentiated and in triple negative BC, and strongly correlated
with worse prognosis. The present study provides the rationale to study in-depth the role of NM at the crossroads of
proliferation and differentiation, and depicts new avenues for the design of novel drug combinations for the treatment of BC.
Introduction
Tumor de-differentiation contributes to the malignant phe-
notype of most solid tumors, including breast cancer (BC)
[1, 2], and in many cases this is achieved through the
epithelial-to-mesenchymal transition (EMT) and the cancer
stem cell (CSC) programs [3–5]. Indeed, EMT and CSC
markers are more frequently found in aggressive poorly
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differentiated (high-grade) tumors in breast [2] and other
cancers [6–10]. Understanding the mechanisms controlling
the differentiation of BC cells can therefore lead to more
effective therapeutics.
Nucleotide metabolism (NM) is classically viewed as a
motor of cellular proliferation [11]. Cancer cells are, in fact,
highly dependent on the de novo synthesis of nucleotides to
produce sufficient DNA and RNA precursors to support
their growth, and some cancer-promoting signaling path-
ways have been shown to regulate NM [12]. However, a
few recent studies have suggested that nucleotides-
generating metabolic pathways may also serve as reg-
ulators of cancer stemness [13, 14], opening the possibility
that some NM enzymes are implicated in cancer cell de-
differentiation.
Thymidylate synthase (TS) is the enzyme that catalyzes the
conversion of deoxyuridine monophosphate (dUMP) to thy-
midine monophosphate (dTMP or thymidylate). Since this
reaction provides the sole de novo pathway for thymidylate
production, TS is essential for DNA synthesis and repair, and
its absence blocks proliferation and causes cell death [15, 16].
We previously discovered that TS expression is correlated
with the EMT phenotype in the NCI-60 transcriptomic data-
base by using a pan-cancer EMT gene ratio (Vimentin/E-
Cadherin, VIM/CDH1) [17], but the mechanistic involvement
of the TS enzymatic activity on EMT/CSCs has never been
shown. Here, we report a novel fundamental role of TS in
maintaining the de-differentiated phenotype of BC cells and
its differential expression in the BC subtypes, with several
potential therapeutic implications.
Material and methods
Cell lines
MDA-MB-231 (ATCC), BT-549 and T-47D (NCI) were
cultured in RMPI-1640 (Sigma), while Hs 578T (DSMZ)
were cultured in DMEM (Sigma). Media were supple-
mented with 10% FBS (Sigma), 1%Pen/Strep (Sigma) and
1%L-Glutamine (Sigma). Cells were STR-profiled, used
between passages 3 and 15, examined for mycoplasma and
maintained in Plasmocin (Invivogen) to prevent con-
tamination. Human umbilical vein endothelial cells
(HUVEC) were cultured in Ham’s F-12K Medium (Gibco)
supplemented with 0.1 mg/ml heparin (Sigma) and 0.03 mg/
ml endothelial cell growth supplement (Sigma) 50 μ/ml Pen/
Strep (Lonza) and 10% FBS (Biowest).
Western blot analysis
Cells were lysed in RIPA buffer and quantified using
the Pierce BCA kit (Thermo-Fisher). Proteins lysates
(10–35 μg) were resolved on 10% SDS–PAGE gels and
transferred to PVDF membrane (Thermo-Fisher). Mem-
branes were blocked in 5% Milk (BioRad) in 1XTBS-T and
incubated overnight in primary antibodies diluted in 5%
milk at 4 °C. Western blot antibodies for TS (EPR4545) and
DPYD (EPR8811) are from Abcam and β-Actin (8H10D10)
is from Cell Signaling. After incubation with secondary
antibodies (Southern Biotech), detection was performed
using the ECL (Thermo-Fisher) and developed on X-Ray
film (Thermo-Fisher) using a chemiluminescence imager,
AGFA CP100.
Proliferation assay
For proliferation assay cells were seeded in 96-well plates in
low density (5–20% initial confluency). Plates were loaded
in IncuCyte ZOOM (Essen BioScience) and scanned every
2–4 h. For each scan, phase contrast image was acquired
from every well and was analyzed by IncuCyte Zoom
software.
Migration assay
For migration assay cells were plated in 96-well plates so
that they reach 90% confluency overnight. Cells were
wounded using WoundMaker (Essen BioScience) as per the
instruction from the manufacturer. Plates were loaded in
IncuCyte ZOOM and were automatically scanned for pro-
grammed time interval. For each scan, wound width was
recorded by the software and the proliferation inside the
wound was normalized to the proliferation outside the
wound, giving relative wound density for each time point.
Cell surface staining and FACS
Anti-CD44-FITC and anti-CD24-PE antibodies are from
Biolegend. For staining, 400,000 cells were plated in 6-well
plate and allowed to grow overnight. Cells were trypsinized
and collected in FACS tubes. After two washes with 1%
FBS/PBS, cells were incubated with 400 ng CD24-PE and
CD44-FITC (diluted in 100 µl 1% FBS/PBS) for 20 min on
ice. Cells were washed twice with 1% FBS/PBS and sus-
pended in 5 mM EDTA and 2% FBS/PBS. CD24/CD44
positivity was recorded in CytoFLEX flow-cytometer
(Beckman Coulter). Gating was done using unstained
cells. FACS data were analyzed using FlowJo (V10.1).
RNA sequencing
Total RNA was extracted using miRNeasy kit (Qiagen)
following the manufacturer’s instructions. RNA-Seq
libraries were constructed using the TruSeq sample Prep
Kit V2 (Illumina). Briefly, 1 μg of purified RNA was
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poly-A selected and fragmented with fragmentation
enzyme. After first and second strand synthesis from a
template of poly-A selected/fragmented RNA, other pro-
cedures from end-repair to PCR amplification were done
according to library construction steps. Libraries were
purified and validated for appropriate size on a 2100
Bioanalyzer High Sensitivity DNA chip (Agilent Technol-
ogies.). The DNA library was quantified using Qubit and
normalized to 4 nM before pooling. Libraries were pooled
in an equimolar fashion and diluted to 10 pM. Library pools
were clustered and run on Nextseq500 platform with paired-
end reads of 75 bases, according to the manufacturer’s
recommended protocol (Illumina). Raw reads passing the
Illumina RTA quality filter were pre-processed using
FASTQC for sequencing base quality control. Sequence
reads were mapped to UCSC human genome build using
TopHat and differential gene expression determined using
Cufflinks 2.1.1 and Cuffdiff2.1.1 as implemented in Base-
Space. Sequencing data has been deposited to publically
available GEO dataset GSE122953.
Bioinformatic analysis
Gene set enrichment analysis (GSEA) on the differentially-
expressed genes (DEGs) upon TS knockdown was per-
formed with the Molecular Signatures Database
v6.1 software. For patient data analysis, normalized gene
expression data from the following patient datasets were
downloaded from GEO database; GSE19783, GSE31448,
GSE19536, GSE58644, GSE21653, GSE45827, and
GSE58812. While GSE58812 is a dataset of triple-negative
BC patients, all other datasets are of BC patients with dif-
ferent subtypes. For calculation of TS Knockdown (KD)
score, first, z scores of the down- and up-regulated genes
upon TS knockdown were calculated. Then, the sum of z
scores of downregulated genes were subtracted from the
sum of z scores of upregulated genes and KD scores were
obtained for each patient. Patients were grouped based on
either their TYMS gene expression or KD score. GSEA was
performed by using patient data from GSE58644 and
GSE58812. Survival graphs were generated in GraphPad
and the significance was assessed by Log-rank test. Survival
graphs from the KM Plotter database was generated based
on TYMS expression by using the auto select best cutoff
option. Statistical analyses were performed by unpaired
student’s t-test.
Quantitative real-time PCR
Total RNA was extracted using miRNeasy kit (Qiagen) and
converted to cDNA using Tetro cDNA synthesis kit (Bio-
line) with random hexamers. 50 nanograms cDNA was used
as template for real-time quantification. GAPDH was used
as the internal control. TaqMan probes (Thermo-Fisher)
were used for quantification in Applied Biosystems 7300.
Fold change was calculated using the ΔΔCt method.
Mouse tail vein metastasis injection
For tail vein metastasis assay, 1.5 × 106 cells were injected
into tail vein of 6–8 weeks old female athymic nu/nu mice,
with three mice per group. Lung metastases were monitored
by bioluminescence imaging (BLI). Anesthetized mice were
intraperitoneally injected with 200 mg/kg D-luciferin (Per-
kin Elmer). Bioluminescence images were acquired with
Lumina III in vivo Imaging System (Perkin Elmer). Ana-
lysis was performed with live imaging software by mea-
suring photon flux. Lungs were collected and fixed in 10%
buffered formalin and processed to obtain paraffin blocks.
Three-micron thick sections of formalin fixed paraffin
embedded samples were stained using hematoxylin and
eosin. Mice experiments were approved by Animal Ethics
Committee of the Bilkent University.
Real-time HUVEC invasion assay (in vitro
extravasation assay)
In vitro extravasation assay was performed as previously
described [18]. Briefly, 2.5 × 104 HUVEC cells in 100 µl
were seeded in E-plates (ACEA xCelligence). Once
HUVEC monolayer formed (19–21 h), 1 × 104 MDA-MB-
231 cells were added on top of the monolayer. A decrease in
cell index indicates invasion through the HUVEC mono-
layer by tumor cells. Penetration of HUVEC monolayer was
monitored for up to 10 h by using xCelligence Real-time
Cell Analyzer (Acea Biosciences).
Chick chorioallantoic membrane (CAM) assay
CAM assay for intravasation was performed as described
previously [19]. Briefly, fertilized white leghorn eggs
(Asby) were incubated in a rotary incubator at 37 oC with
60% humidity for 10 days. The CAM was dropped by
drilling a small hole through the eggshell into the air sac and
a second hole near the allantoic vein that penetrates the
eggshell membrane but not the CAM. The CAM was
dropped by applying a mild vacuum to the hole over the air
sac. Subsequently, a cutoff wheel (Dremel) was used to cut
a 1 cm2 window, encompassing the second hole near the
allantoic vein to expose the underlying CAM. The CAM
was gently abraded with a sterile cotton swab to provide
access to the mesenchyme and 50 μl inoculum of 2 × 106
MDA-MB-231-pLKO (n= 10) or MDA-MB-231-shRNA-
TS#2 (n= 10) cells were applied. Four eggs without human
cells are used as negative control. The windows were sub-
sequently sealed and the eggs returned to incubator. The
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eggs remained in the incubator for further 2 days, following
which the CAM was cut into two halves and the tumor was
excised from the upper CAM and the genomic DNA was
extracted from the lower CAM. The lower CAM genomic
DNA was then analyzed for the presence of human cells by
quantitative Alu PCR with 500 ng cDNA. The number of
intravasated human cells was then plotted in the graph as
shown.
Deoxynucleotide triphosphate quantification
The cellular dNTP levels were determined by the RT-based
dNTP assay [20]. Briefly, the cellular dNTPs in experi-
mental triplicates were extracted by methanol, and the
determined dNTP amounts were normalized for an equal
cell number (1 × 106).
TS enzyme activity quantification
TS was quantified in MDA-MB-231 cells as previously
described [21]. Briefly, cells were collected and pelleted.
Cells were suspended in 300 µl ice-cold Reaction mix (RM,
20 mM MgCl2, 1.5 mM NaF, 1 mM DTT in 50 mM Tris-
HCl pH 7.5, after deoxygenation 0.47 (v/v%) BME was
added. Next, cell lysates were prepared on ice by applying
15 pulses with a Branson 250 tip sonicator (Branson) at
power input setting level 3 with a 50% duty cycle. After
centrifugation at 11000 g for 20 min at 4 °C, 95 µl of
supernatant was transferred to a clean 1.5 ml vial on ice for
immediate determination of protein followed by TS activity
analysis. Protein concentrations in PBMC cytosolic lysates
were determined using the Bio-Rad protein assay (Bio-
Rad). Briefly, 5 µl of PBMC cytosolic lysate was diluted
with 45 µl of MilliQ water (Millipore). Five bovine serum
albumin standards were prepared in concentrations ranging
from 32.5 to 500 mg/ml to obtain a standard curve. In
duplicate 10 µl of diluted lysate and the standard curve were
transferred to a clear 96-well flat bottom plate. After the
addition of 200 µl dye solution, the plate was incubated for
15 min at RT and subsequently the absorption was mea-
sured at 590 nm using an EL340 microplate reader (Bio-
Tek). Immediately before the start of TS activity assay, a
vial containing 2.51 mg of lyophilized MTHF was recon-
stituted in 500 µl of deoxygenized water and 10 µl was
added to a 2.0 ml vial on ice. To this vial 85 µl of ice-cold
tumor cell cytosolic lysate corresponding to 15 µg of protein
was added. Next, 5 µl of 1 mM ice-cold substrate was
added, and after mixing, the samples were incubated for 3 h
at 37 °C in a shaking water bath. The reaction was termi-
nated by adding 100 µl of 6.5 N HCl, and the remaining
substrate was bound onto 400 µl Carbon slurry (CS, 5 g acid
washed charcoal, 50 mg Dextran T500 in phosphate buf-
fered saline) by vertical disk rotation mixing of the samples
at 50 rpm at 4o C. After centrifugation at 11,000 g for 5 min
at 4 °C, 300 µl of clear supernatant was transferred to a
20 ml polyethylene vial, mixed with 10 ml of Ultima Gold,
and assayed for radioactivity for 5 min using a LSC2900
Tri-Carb liquid scintillation counter.
Lentiviral transduction
Plasmids for TS (TRCN000045663/66/67) and DPYD
knockdown (TRCN000025799) are from Sigma. Empty
vector (pLKO) was used as control. For TS reconstitution,
plasmids were purchased from GeneCopoeia in which silent
mutation was introduced in shTS#1 binding region (5′-
G483CAAAGAGTAATCGATACAAT503–3′). Enzymati-
cally inactive TS expression vector was generated by
introducing single point mutation (5′-C148GC150–3′→5′-
TGC-3′) in reconstitution vector. Empty vector (CS-T0406-
LV151) was used as control. TS expression vector (Ex-
T0406-LV105b) and control vector (Ex-Neg-LV105b) are
from GeneCopoeia. For production of lentiviral particles,
293T cells were transfected with 8 µg knock-down/expres-
sion vectors and 2 µg of pMDL, pVsVg and pRevRes in
complex with 24 µg PEI (Polysciences). After 48 h, super-
natant was collected, centrifuged and filtered. For trans-
duction, 100,000–150,000 cells were seeded in 6-well plate
and infected presence of 8 μg/ml polybrene (Sigma).
Selection was done with 3 μg/ml puromycin (Sigma) and
cells were maintained in 1 µg/ml puromycin. MDA-MB–
231 cells infected with TS reconstitution vectors were
selected in 800 µg/ml G418 (Sigma) and cultured in 250 µg/
ml G418.
Mammosphere culture
Forty thousand cells were seeded in triplicates in ultra-low
attachment 6-well plates (Corning) in complete Mammocult
medium (Stem Cell Technologies), prepared according to
the manufacturer’s instruction. After formation, spheres
were counted by spinning at 300 g for 5 min and suspending
in PBS (Lonza).
In vitro cell treatment
Pemetrexed was purchased from Sigma, dihydrothymine
(DHT) was purchased from Selleckchem and were dis-
solved in DMSO to final concentration of 100 mM and
40 mM respectively. Cisplatin was purchased from Santa
Cruz Biotechnology and was dissolved in PBS to the final
concentration of 80 mM. For in vitro treatment cells were
plated in 96-well plates (MDA-MB-231= 3000–4000 cells/
well and T-47D= 6000 cells/well) and incubated overnight.
For cytotoxicity death assay, 2000X Cytotox Green
Reagent (Essen BioScience) was diluted in RPMI and
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working dilutions of pemetrexed and cisplatin were pre-
pared in Cytotox Green supplemented media. Working
dilutions of DHT were prepared in RPMI (without Cytotox
Green). After treatment, plate was loaded in Incycuyte
Zoom and images were acquired in real-time for phase to
quantify growth. Activity of Cytotox reagent was simulta-
neously acquired at the green channel to quantify death.
Incycuyte Zoom software was used for the analysis and data
export.
Patients and samples
Formalin-fixed paraffin embedded samples of a series of
120 consecutive breast carcinomas collected between 2010
and 2013 at the Azienda Ospedaliera Universitaria Città
della Salute e della Scienza di Torino were analyzed. All
cases were reviewed and anonymized using an alpha-
numerical code. The main patients’ characteristics are
shown in Supplementary Table 2. The use of retrospective
solid tumor tissues for the immunohistochemical study was
approved by the Ethic Institutional Review Board respon-
sible for “Biobanking and use of human tissues for
experimental studies” - Department of Medical Sciences,
University of Turin.
Immunohistochemistry staining and scoring
Three micrometer thick sections of formalin fixed paraffin
embedded samples were stained for immunohistochemistry
with the EPR4545 antibody (Abcam, 1:150 dilution).
Immunohistochemistry was performed using an automated
slide-processing platform (Ventana BenchMarck XT
Autostainer). The antibody was optimized on FFPE cell
block sections of MDA-MB-231 cells and on human tonsil
tissue. Positive and negative controls were included for each
immunohistochemical run. Immunoreactivity was assigned
based on the proportion of positive tumor cells over total
tumor cells (percent positivity) ranging from 0 to 100%.
Staining intensity was evaluated as negative, faint, moder-
ate, and intense. If the staining intensity was heterogeneous,
then scoring was based on the greatest degree of intensity.
Data were integrated in the H-score, calculated as follows:
H-score= ΣPi (i+ 1), where i represents the intensity of
staining (0–3+), and Pi stands for the percentage of stained
tumor cells (0–100%).
Statistical analysis
Statistical tests were performed with the GraphPad software
v.7 comparing groups of different conditions with repli-
cates. In all tests, the statistical significance was set at p=
0.05 (in the figures * indicates p < 0.05, **p < 0.01, ***p <
0.001).
Results
TS expression correlates with aggressive form of BC
In order to study the association of TS expression with EMT
markers in BC, we employed a VIM/CDH1 ratio to classify
the BC cell lines belonging to the CCLE dataset (n= 52)
into epithelial, mesenchymal or intermediate phenotypes
(Fig. 1a and Supplementary Table 1. Comparing epithelial
(VIM/CDH1 < 2) with mesenchymal cells (>2), a sig-
nificantly higher expression of TYMS mRNA was found in
the latter (p < 0.005, Fig. 1b). Then, in order to test TS gene
expression in the spectrum of BC patients, we analyzed
three independent GEO datasets, and found that TS
expression was significantly different among the BC sub-
types. Normal-like samples or the well-differentiated
tumors (like luminal A) exhibited low TS expression,
whereas high TS levels were found in basal-like BC
(Fig. 1c). BC with a basal-like gene signature are primarily
triple-negative (TN), and are frequently enriched for and
EMT markers [22].
TS is a marker of more aggressive, chemoresistant,
and EMT-driven BC
In order to test the clinical significance of the TS protein
and its association with the aggressive phenotype in BC,
immunohistochemistry (IHC) was performed on formalin-
fixed paraffin-embedded samples from 120 BC patients.
Patients’ characteristics are shown in the Supplementary
Table 2. TS staining was quantified by an IHC score and
significantly higher expression was found in the TNBC, as
compared to Luminal-A (Fig. 2a) and in high grade (G3)
compared to low grade tumors (Fig. 2b, c). A moderate
level of correlation was found between TS and Ki67 pro-
liferation marker (Rs= 0.48, Supplementary Fig 1A). Ana-
lysis of the prognostic values using large patient datasets
indicated TS expression as a marker for poor overall sur-
vival in BC (all subtypes, Fig. 2d). Of note, TS prog-
nostically stratified luminal A and luminal B patients
(Fig. 2e) as well as lower grade patients (Fig. 2f), while no
association was not found in more aggressive BC (Sup-
plementary Fig 1B).
Moreover, since TS is a common anti-cancer drug target,
being required for DNA repair and directly inhibited by
compounds like pyrimidine or folate analogues [23], we
additionally tested if change in TS expression altered BC
cells’ sensitivity to the anti-folate drug pemetrexed and to
cisplatin, in a similar fashion as previously observed in
NSCLC [19] [24]. As a result, we found that MDA-MB-231
cells were sensitized to in vitro drug treatment after TS
knockdown (Fig. 2g, h), whereas TS-low T-47D cells,
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overexpressing ectopic TS, showed increased resistance
(Fig. 2i, j).
TS is essential for the maintenance of a de-
differentiated stem-like state in BC
The patient data prompted us to test whether TS plays direct
role in maintaining the de-differentiated state of TNBC.
Hence, we transduced the TNBC cell line MDA-MB-231
with lentiviruses containing non-overlapping shRNA
sequences to knockdown TS (Fig. 3a). CD44/CD24 surface
staining followed by FACS quantification indicated an
increase in the population of differentiated CD24+ cells,
with a concomitant decrease in the CD44+CD24− BC stem
cell population (Fig. 3b). In order to carefully monitor the
effects on cell growth, the confluency of infected cells was
examined with real-time proliferation assays after TS
depletion. The results showed a significant suppression of
proliferation in cells infected with the shRNA that delivered
a strong TS repression (shTS#2), while the sequence with a
mild knockdown (shTS#1) did not alter the cells’ growth
(Fig. 3c). By contrast, a shRNA (shTS#3) sequence that
induced a complete TS elimination in this cell line caused a
massive growth arrest and death (Supplementary Fig. 2A,
B), in line with the life-essential role of TS. To determine if
the partially TS-deficient cells had reduced ability to
migrate, we performed a real-time wound-healing assay
where cell migration is corrected for proliferation outside
the wound to account for changes in cell growth rate upon
TS repression. The results showed a significant loss of
migratory ability upon TS knockdown (Fig. 3d, e). More-
over, assayed for stemness-related functional phenotype,
TS-deficient cells formed less mammospheres in low-
adherent cultures (Fig. 3f, g). Comparable findings were
obtained in other TNBC cell lines, such as Hs 578T
(Fig. 3h–k) and BT-549 (Supplementary Fig. 3A–D),
implying that TS could be a common EMT/CSCs regulator
in TNBC.
Finally, to test the in vivo effects of TS suppression,
MDA-MB-231-luc cells with TS knockdown or non-
targeting control cells were injected in the tail-vein of
nude mice. Interestingly, a significantly higher luciferase
signal was recorded from shTS cells compared to control
cells (Fig. 4a, b). Histological analysis confirmed the pre-
sence of single or multiple metastatic deposits of various
size (ranging from <1 to 2 mm) and signs of lympho-
vascular invasion only in mice injected with shTS cells (not
shown). The increased ability of TS-deficient cells to form
metastasis was independently confirmed by an in vitro real-
time extravasation assay, which monitors how fast the
cancer cells penetrate a monolayer of human umbilical vein
endothelial cells (HUVEC) (Fig. 4c). In addition, to monitor
the intravasation ability, a CAM assay on chicken embryos
was performed (Fig. 4d), which confirmed an increased
ability of TS-deficient cells, seeded on the upper CAM, to
intravasate into the lower CAM (Fig. 4e). These observa-
tions clearly pointed at a strong impact of TS on BC dif-
ferentiation and alteration of cells’ behavior, which we
aimed to further molecularly characterize.
TS knockdown induces loss of EMT and correlates
with less aggressive BC
To further delineate the molecular pathways regulated via
TS and involved in mediating the de-differentiation pro-
gram in BC, we subjected shTS#1 MDA-MB-231 cells to
Fig. 1 TS expression correlates
with aggressive form of BC.
a Vimentin/E-cadherin (VIM/
CDH1) ration in BC cell lines
belonging to the CCLE database
(gene expression). Cells were
sorted in epithelial (n= 27),
EMT-intermediate (n= 6) and
mesenchymal (n= 19)
phenotype. b Comparison of TS
mRNA expression levels
between epithelial and
mesenchymal BC cell lines (p=
0.0039, two-tailed t-test). c TS
mRNA levels in BC tissues
divided according to molecular
subtypes in indicated GEO
datasets (p < 0.0001 in all
datasets, compared between
luminal A and basal subtypes,
one-way ANOVA, Turkey’s
multiple comparison)
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RNA-sequencing. These cells were selected because they
had a discernable change in the CD24+ population but no
major proliferation defect, so to analyze proliferation-
independent effects. By setting a stringent cutoff value of
2-fold to identify DEGs compared to non-targeting infected
cells (pLKO), we found 73 and 84 genes down and up-
regulated, respectively (Supplementary Table 3). Pathway
analysis (GSEA) revealed that EMT was the most sig-
nificantly deregulated pathway, followed by TNF-α/NFκ-β
signaling (Fig. 5a), known to be functionally connected
with EMT in BC [25]. RNA-seq data were validated by
qPCR (Fig. 5b, Supplementary Fig. 4A) and were used to
explore the prognostic significance of the gene signature
associated with TS-knockdown. A system biology approach
was adopted to investigate different BC gene expression
datasets, dividing the patients by low or high KD score
(corresponding to high or low TS, respectively). As a fur-
ther confirmation of a strong association with EMT, a pre-
viously established signature of genes up-regulated during
EMT [26] was found significantly enriched in patients with
a low TS KD score (Fig. 5c). Moreover, a gene set pre-
dicting poor prognosis was found enriched in patients with
low KD score (Fig. 5d), and similar associations with the
grade of differentiation were found using both the TS KD
Fig. 2 TS is a marker of aggressive, chemoresistant and EMT-driven
BC. a Immunohistochemical staining of TS in FFPE samples from BC
patients (n= 120) segregated according to molecular subtype or
b grade of differentiation (p= 0.0237 between luminal A and TNBC
and 0.0119 between Grade I and III, one way ANOVA, Turkey’s
multiple comparison). Grade III are poorly differentiated cancers. c
Representative images showing H&E and TS staining in well-
differentiated and poorly-differentiated tumors (scale bars represent
100 µm). Kaplan–Meier curves showing the prognostic significance of
TS expression in BC (all types) (d), in luminal (e), and in low grade
patients (f). P-values are log-rank tests and HR is hazard ratio. MDA-
MB-231 cells with shTS#1 knockdown, treated with (g) 1.5 mM
pemetrexed and (h) 500 µM cisplatin (p= 0.0019 for pemetrexed and
<0.0001 for cisplatin, between treatment of shTS#1 and pLKO, two
way ANOVA, Turkey’s multiple comparison). Death is recorded as
green objects that represent the dying cells that incorporate Cytotoxic
Green dye. T-47D cells overexpressing TS (TS, red) and empty vector
(Vector, black) treated with 1.5 mM pemetrexed (i) and 50 µM cis-
platin (j) in presence of Cytotoxic Green dye (p= 0.0009 for peme-
trexed and 0.0341 for cisplatin, between treatment of empty vector and
TS, two-way ANOVA, Turkey’s multiple comparison). Experimental
data are representative of at least two independent experiments with
similar results. Points are avg ± SD
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score and TS expression to segregate the patients (Supple-
mentary Fig. 4B, C). Survival analysis showed a strong
prognostic impact of the TS-knockdown signature, indi-
cating a poorer prognosis for the patients with a lower score
or higher TS in all subtypes (Fig. 5e), and a trend for a
significant impact in TNBC (Fig. 5f). The KD score was
also significantly correlated with all the major histopatho-
logical variables in BC, including histology, grade of dif-
ferentiation and size of the tumors (Fig. 5g–j). All these
data together indicate that TS promotes EMT-driven
aggressive BCs.
TS enzymatic activity and thymidine catabolism are
essential for maintaining BC de-differentiation
We then aimed at determining the impact of TS enzymatic
activity on de-differentiation. TS is the only de novo source
of thymidylate (dTMP), which is either further phosphory-
lated to maintain the dNTP pools for DNA synthesis, or
directed to degradation via sequential phosphorolytic clea-
vages. MDA-MB-231 shTS#1 cells where subjected to
dNTP quantification, but, consistently with the previously
observed normal growth, no significant change in dTTP or
Fig. 3 TS knockdown suppresses the mesenchymal phenotype of
TNBCs. a Efficiency of TS knockdown in MDA-MB-231 obtained
with shRNA lentiviral particles. pLKO is non-targeting control.
b FACS plots of MDA-MB-231 cells as in a stained with CD44-FITC
and CD24-PE. Gates are based on unstained control cells. c Real-time
measurement of growth (confluency) in MDA-MB-231 with shTS or
control cell (p= ns for shTS#1 and <0.0001 for shTS#2, as compared
to pLKO, two-way ANOVA, Dunett’s multiple comparison). d Real-
time migration assay in MDA-MB-231 cells with TS knockdown (p <
0.001 for shTS#1 and shTS#2, as compared to pLKO, two-way
ANOVA, Dunett’s multiple comparison) and e representative pictures
showing wound width at different time points (scale bar represents
300 µm). f Relative counts of spheres (p= 0.0012 for shTS#1 and
0.0001 for shTS#2 as compared to pLKO, one way ANOVA, Dunett’s
multiple comparison) and g representative pictures of spheres formed
by TS knockdown cells (scale bar represents 400 µm). h Efficiency of
TS knockdown in Hs 578T obtained with shRNA lentiviral particles.
i FACS plot of shTS and pLKO cells showing the expression of cell
surface CD24/CD44. j Effect of TS knockdown on migration of Hs
578T cells (p= 0.0016, two-way ANOVA, Sidak’s multiple compar-
ison). k Relative counts of spheres in Hs 578T TS knockdown cells as
compared to pLKO (p= 0.0011, unpaired Student’s t-test). Experi-
mental data are representative of at least two independent experiments
with similar results. Points are avg ± SD
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other dNTPs was detected (Fig. 6a). This suggested that the
differentiation observed in shTS cells was not caused by
dNTP imbalance, as shown in other CSC models upon
knockdown of specific NM-related enzymes [13], and that
while a baseline TS level is required for the cells to grow,
increased TS activity could be partly involved in other
cellular functions. To functionally investigate the role of TS
enzymatic activity, we reconstituted shTS#1 cells with
either a wild type (TSwt) expressing silent mutation in
shRNA binding region or an enzymatically inactive
(TSR50C) form of TS [27]. Western blotting confirmed the
successful transduction (Fig. 6b) and TS enzymatic activity
assay confirmed the loss of catalytic activity in the TSR50C
overexpressing cells (Fig. 6c). Strikingly, MDA-MB-231
cells overexpressing the TSwt enzyme increased prolifera-
tion (Fig. 6d), reduced the population of differentiated
CD24+ cells (Fig. 6e), formed more mammospheres
(Fig. 6f) and were significantly more migratory (Fig. 6g)
compared to TSR50C cells overexpressing the catalytically
inactive TS.
These results clearly indicated that the TS enzymatic
activity is essential for the maintenance of the EMT/CSCs
phenotype. We therefore hypothesized that TS mediates de-
differentiation via the nucleotide catabolism (Fig. 7a), rather
than through the pathway leading to DNA synthesis. This
was supported by the results of a recent shRNA screen on
human immortalized breast cells, which revealed that pyr-
imidine catabolism mediated by dihydropyrimidine dehy-
drogenase (DPYD) was responsible for the EMT phenotype
[28]. We therefore speculated existence of a TS-DPYD axis
controlling EMT/CSCs in BC cells. Although DPYD
mRNA expression did not show a significant prognostic
role in BC patients (Supplementary Fig. 5A, B), analysis of
expression data from the CCLE showed a marked increase
in mesenchymal-like BC cells not only for DPYD, but also
for the NT5E (CD73), which is one of the upstream 5′-
nucleotidase responsible for catalyzing the first step of
dTMP degradation (Fig. 7b). In order to functionally prove
our hypothesis, we knocked down DPYD (Fig. 7c) and
observed a significant increase in the population of CD24+
cells (Fig. 7d) and a loss of migratory ability (Fig. 7e), in
line with what we observed in TS-deficient cells. However,
the CD24+ enriching effect of DPYD knockdown could not
be reverted by overexpressing TS (Fig. 7f), suggesting that
TS enzymatic control of de-differentiation requires a
DPYD-dependent pyrimidine catabolism. To further con-
firm it, we tested if the supplementation of DPYD enzy-
matic product DHT in medium could rescue the
differentiation phenotype observed in TS knockdown cells.
As a result, DHT supplementation significantly increased
the counts of sphere (Fig. 7g) and reduced the CD24+
population (Fig. 7h) in TS knockdown cells, having no
effect on the cell proliferation (Supplementary Fig. 5C). In
summary, our data indicate that TS enzymatic activity and
pyrimidine catabolism are essential for the maintenance of
the BCSC phenotype. We therefore propose a model in
which dTMP produced by TS-overexpressing cancer cells is
not only metabolized to support the uncontrolled pro-
liferation, but can also partially sustain de-differentiation
and EMT via DPYD-based pyrimidines degradation
(Fig. 8).
Discussion
The aggressiveness and the de-differentiated phenotype of
neoplastic cells have been strongly connected with altera-
tions in specific metabolic pathways, especially those
involved in the transformation of glucose [29–31], while the
contribution of other pathways is still majorly unexplored.
Fig. 4 Ablation of TS expression alters the invasive ability of TNBC
cells. a Representative images of lung metastasis formation assay
performed by injecting luciferase-expressing MDA-MB-231 cells in
the tail-vein of nude mice (n= 3/group). b Quantification of the bio-
luminescence signal from the lung metastases (p= 0.0078, unpaired
two tailed t-test). c Relative ability of TS knockdown or control cells to
penetrate through a HUVEC monolayer in an in vitro extravasation
assay (p= 0.00065 unpaired multiple t-test). d Sketch diagram
representing the chorioallantoic membrane (CAM) assay and e quan-
tification of control and MDA-MB-231 shTS#2 intravasation in lower
CAM, 2 days after seeding in the upper CAM (p= 0.0012, multiple
t-test). Experimental data are representative from at least two inde-
pendent experiments with similar results. Points are avg ± SD
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Elevation in NM is typically associated with the tumor
cells’ increased demand for DNA precursors to sustain the
uncontrolled proliferation [11]. However, a few studies
have shown that some NM enzymes are functionally
involved in de-differentiation processes, like the ecto-
nucleotidase ENPP1 in the maintenance of the CSCs-like
state in glioblastoma [13]. Similarly, treatment with non-
toxic doses of TS-inhibiting drugs was found sufficient to
induce a differentiation in multiple myeloma CSCs and
sensitize the cells for radiotherapy [14]. These observations,
together with the first demonstration of a connection
between TS and EMT [17], prompted us to investigate the
EMT-driven TNBC model [3, 22]. Functional experiments
clearly indicates that loss of TS altered the de-differentiated
phenotype of TNBCs, reducing CD44+CD24− cells, and
suppressing migratory and sphere-forming ability. Con-
sistently, this was accompanied by a robust suppression of
EMT-associated genes, as evaluated by RNA-seq analysis.
In vivo, two independent animal models, confirmed by an
in vitro extravasation assay, revealed an augmented pro-
pensity for intravasation and metastasis formation in cells
with TS knockdown. These findings are in line with pre-
vious reports in which EMT-suppressing conditions
enhanced the metastatic colonization capacity of
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Fig. 5 TS knockdown suppresses EMT and the associated gene sig-
nature correlates with less aggressive BC. a Gene set enrichment
(GSEA) analysis showing the most differentially regulated pathways
in MDA-MB-231 with TS knockdown (RNAseq data). b qPCR vali-
dation of RNA-seq results in MDA-MB-231 shTS#1. Bars are avg ±
SEM. GSEA of TS low and high TS KD score (derived from RNA-
seq) with previously published (c) EMT and d BC poor prognosis gene
signatures, representing NSE (Normalized Enrichment Score) and
p-value. Kaplan-Meier curves of e overall survival and f metastasis-
free survival in cancer patients stratified by TS KD score. P-values are
log-rank tests. TS KD scores in BC patients divided by g–h molecular
subtype (p= 0.0022 for GSE19536 and 0.0333 for GSE45827,
unpaired two tailed t-test), i grade of differentiation (p < 0.0001,
unpaired two tailed t-test), and j TNM tumor size (p= 0.0091, one-
way ANOVA, Turkey’s multiple comparison). Experimental data are
representative from at least two independent experiments with similar
results
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mesenchymal-like BC cell lines [32, 33], and a plausible
explanation comes from recent studies, which found that the
tumor-initiating and metastatic potential is maximum when
breast and other cancer cells are in an intermediate EMT
(hybrid) state [34–38], leading to a partial revision of the
initial model of EMT in cancer metastasis [35, 39, 40]. Our
in vivo data therefore reflect the complicated nature of
EMT, which may also vary in a context-dependent fashion
[39, 41]. Targeting TS in other cells, in fact, exerted a clear
anti-metastatic effect [42]. Nevertheless, both the immu-
nohistochemical quantification of TS protein levels and the
TS knockdown scores derived from the RNA-seq data were
strongly associated with BC de-differentiation and prog-
nosis, indicating a pivotal role of TS in the malignancy of
BC. Interestingly, only a moderate co-expression between
TS and the proliferation marker Ki67 was found, in line
with previous data from other cancers [43, 44], supporting
our model that TS activity could be implicated in other
cellular functions independent of proliferation. We found, in
fact, that the EMT/CSC suppression imposed by a level of
TS knockdown, which did not perturb cells’ proliferation
and dNTP balance was rescued by overexpressing wild-type
TS, but not by a catalytically inactive mutant. This was
particularly important because it ruled out the possible
contribution of non-enzymatic activities of TS [45], directly
pointing at the enzymatic activity as the EMT/CSC driving
force. Since dihydropyrimidine accumulation was pre-
viously shown to control EMT in BC [28], we tested and
demonstrated the hypothesis that high TS enzymatic activity
in cancer cells sustains de-differentiation and EMT via a
DPYD-dependent pyrimidine catabolism. Several follow-up
studies are needed, for instance, to (1) test by IHC the
significance of DPYD in BC, and to identify the mechan-
isms by which DHT controls EMT/CSC, to understand if
the underlying pathways could represent novel valuable
therapeutic targets; (2) address the impact of other dTMP-
transforming enzymes (like NT5E/CD73) and salvage
pathways on EMT; (3) identify the regulatory pathways
upstream of the TS-DPYD axis; (4) test a similar function
for TS in other malignancies; (5) decipher the contribution
of TS dysregulation to cancer-relevant pathways other than
EMT (like inflammation). In any case, our data assert that
the classical role of TS as a mere proliferation marker needs
to be revisited. For instance, the previously identified
oncogenic and tumor-initiating role of TS [27, 46] could be
explained with the direct/indirect control of de-
differentiation and stemness. The present data add the
control of de-differentiation to the list of functions of TS
Fig. 6 TS enzymatic activity is essential for maintenance of BC de-
differentiation. a Quantification of deoxyribonucleotide triphosphate
(dNTPs) in MDA-MB-231 cells with TS knockdown and control cells.
b Reconstitution of enzymatically inactive (TSR50C) or wild-type
(TSwt) TS in MDA-MB-231 shTS#1 cells. c Measurement of TS
enzymatic activity in MDA-MB-231 shTS#1 cells expressing TSR50C
or TSwt (p < 0.0001, unpaired two tailed t-test) (d) Proliferation
(p= 0.0001, two-way ANOVA, Dunnett multiple comparison),
e CD44/CD24 FACS profile, f sphere-forming ability (p < 0.0001,
unpaired two tailed t-test), and g migration capacity (p < 0.0001, two-
way ANOVA, Turkey’s multiple comparison) of cells that express
either TSR50C or TSwt. Experimental data are representative from at least
two independent experiments with similar results. Points are avg ± SD
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(together with proliferation and DNA repair) that can affect
the prognosis of BC patients. More efforts will need to be
dedicated to clarify how the cancer cells balance prolifera-
tion and differentiation, and to what exact extent other
nucleotide metabolic genes are implicated in these
processes.
TS is a well-established target of chemotherapy, being
inhibited by drugs like 5-fluorouracil (5-FU) or by folate
analogues [23], and its overexpression in tumors represents
a major mechanism of chemo-resistance. From the transla-
tional point of view, our finding that TS levels can be sig-
nificantly different among BC subtypes contradicts earlier
works [47] and may be useful to improve the treatment
strategies. In our study, TS was found higher in the
aggressive BC and in high-grade tumors, in line with pre-
vious observations in other cancers [43, 44, 48], and this
information could be clinically important for predicting the
efficacy of anti-TS drugs. The present study, as well as
other pivotal works [49], can therefore anticipate subtype-
specific susceptibilities to anti-TS drugs in BC. However,
these results also highlight the clinical importance of care-
fully assessing the potential impact of TS-inhibition on
metastasis formation and, therefore, further in vivo work
and retrospective studies are warranted.
Fig. 7 TS regulates de-differentiated tumor phenotype via DPYD-
mediated thymidine catabolism. a Scheme of the thymidylate catabolic
pathway. b DPYD (p= 0.0031) and NT5E (p= 0.0001) mRNA
expression levels in epithelial and mesenchymal BC cell lines (CCLE
dataset). The statistical tests are unpaired two tailed t-test. c Western
blot quantification of DPYD knockdown in MDA-MB-231, and the
effects on (d) CD44/CD24 profile and e migratory ability (p < 0.0001,
two-way ANOVA, Sidak’s multiple comparison). f FACS plots of
MDA-MB-231 cells with DPYD knockdown overexpressing TS or an
empty vector and stained with CD44/CD24. g Sphere counts for
shTS#1 cells in MDA-MB-231 (p < 0.0394 between pLKO and NT,
p < 0.0001 between NT and DHT) and BT-549 (p < 0.0001 between
pLKO and NT, p= 0.0023 between NT and DHT, one-way ANOVA,
Turkey’s multiple comparison) after treatment with 1 µM dihy-
drothymine (DHT). NT (DMSO) is the non-treated control. h CD24/44
profile showing the effect of 10 µM DHT on CD24+ population in
MDA-MB-231 cells with TS knock-down. Points are avg ± S
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